Why the study?
The optimal combination and duration of antithrombotic therapy in ACS remains debated, prompting a comparison between a recent European expert consensus document and the 2023 ESC guidelines.
This review highlights the similarities and differences between the 2023 ESC guidelines and a recent European expert consensus on antithrombotic therapy in ACS patients.
Answers are grounded in this paper and cite their sources.
Clinicians face conflicting ACS antithrombotic advice; leaves open harmonization of consensus with ESC recommendations.
Antithrombotic therapy represents the cornerstone of the pharmacological treatment in patients with acute coronary syndrome (ACS). The optimal combination and duration of antithrombotic therapy is still matter of debate requiring a critical assessment of patient comorbidities, clinical presentation, revascularization modality, and/or optimization of medical treatment. The 2023 European Society of Cardiology (ESC) guidelines for the management of patients with ACS encompassing both patients with and without ST segment elevation ACS have been recently published. Shortly before, a European expert consensus task force produced guidance for clinicians on the management of antithrombotic therapy in patients with ACS as well as chronic coronary syndrome. The scope of this manuscript is to provide a critical appraisal of differences and similarities between the European consensus paper and the latest ESC recommendations on oral antithrombotic regimens in ACS patients.
No takes yet. Share an insight, caveat, or question.
Landi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: